drug · small molecule
dexamethasone SR
Phase 3updated 5mo agoby $OCUL OCULAR THERAPEUTIX, INC🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- tagApproval82 co-mentions · 21 sources
- drugOZURDEX40 co-mentions · 20 sources
- drugdexamethasone LA28 co-mentions · 14 sources
- tagOphthalmology12 co-mentions · 6 sources
- drug(dexamethasone + tobramycin)12 co-mentions · 6 sources
- tagRecall11 co-mentions · 9 sources
- drugdexamethasone sodium phosphate8 co-mentions · 3 sources
- drugdexamethasone sodium phosphate SR8 co-mentions · 3 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.
targets
Glucocorticoid receptor
all catalysts(0)
nothing on the calendar yet
Trials studying dexamethasone SR
- phase1An Investigational Study of Hydrocortisone
- phase3A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- phase2Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- phase3A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- phase3A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that